Global Next Generation Sequencing (NGS) Market, By Product & Service (Consumables, Services, and Instruments), Technology (Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), and Others), Application (Pharmaceuticals Microbiology, Drug & Biomarker Discovery, Diagnostics, Precision Medicine, Agricultural & Animal Research, Food Pathogen Screening, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinics, Clinical Laboratories, Contract Research Organizations (CROS), and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Next Generation Sequencing (NGS) Market Analysis and Size
The global next generation sequencing (NGS) market is driven by the increasing demand for personalized medicine and the growing adoption of NGS technologies in clinical diagnostics and research applications. However, one restraint for market growth is the high cost associated with NGS procedures, limiting its accessibility in developing regions. An opportunity in this market lies in the advancements in NGS technologies, such as improved data analysis tools and faster sequencing platforms, which can enhance the efficiency and accuracy of sequencing processes. One challenge is the need for standardized protocols and regulations for NGS-based tests to ensure consistency and reliability across different laboratories and healthcare settings.
Data Bridge Market Research analyzes that the global next generation sequencing (NGS) market is growing with a CAGR of 15.1% in the forecast period of 2024 to 2031 and is expected to reach USD 40.78 billion by 2031 from USD 13.88 billion in 2023.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product & Service (Consumables, Services, and Instruments), Technology (Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), and Others), Application (Pharmaceuticals Microbiology, Drug & Biomarker Discovery, Diagnostics, Precision Medicine, Agricultural & Animal Research, Food Pathogen Screening and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinics, Clinical Laboratories, Contract Research Organizations (CROS), and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa
|
|
Market Players Covered
|
Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Merck KGaA, Charles River Laboratories, Revvity, Promega Corporation., Agilent Technologies, Inc., Takara Bio Inc., Eurofins Scientific, Hamilton Company, BGI, Azenta US, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., PacBio., Macrogen, Inc., Gilson Incorporated, New England Biolabs, Oxford Nanopore Technologies plc., LGC Biosearch Technologies, PCR Biosystems, ACT Genomics, Quantabio, DNASTAR, and NimaGen. among others
|
Market Definition
Next Generation Sequencing (NGS), also identified as high-throughput sequencing, is a powerful technology used for rapidly sequencing DNA and RNA. Unlike traditional sanger sequencing, which is slower and more expensive, NGS allows for the simultaneous sequencing of millions of DNA fragments, enabling researchers to quickly and efficiently analyze large genomes, identify genetic variations, and study gene expression patterns. NGS has revolutionized genomics research, enabling new visions into the genetic basis of diseases, the diversity of microbial communities, and the evolution of species.
Global Next Generation Sequencing (NGS) Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Increase in the Adoption of Genome-Focused Pharmacology
The increasing adoption of genomic pharmacology is acting as a major driver for the global next generation sequencing (NGS) market, transforming the landscape of personalized medicine and targeted therapies. As healthcare providers recognize the value of tailoring treatments based on individual genetic profiles, the demand for high-throughput, accurate genomic sequencing has surged. NGS technologies enable comprehensive analysis of a patient's genome, allowing for precise identification of genetic variants that influence drug response, resistance, and potential adverse effects. This level of personalized insight guides clinicians in selecting the most in effect and safe treatments for each patient, improving outcomes and reducing trial-and-error prescribing. As a result, the NGS market is expanding rapidly, fueled by the growing adoption of genomic pharmacology across various medical fields and its potential to revolutionize patient care and outcomes.
- Wide Product Portfolio Offered by Major Players
A wide product portfolio offered by market players is a key driver for the growth of the global next generation sequencing (NGS) market, as it provides customers with a comprehensive variety of solutions to meet diverse research and clinical needs. By offering a variety of NGS platforms, consumables, and software, market players can cater to different levels of research complexity, throughput requirements, and budgetary constraints. This versatility agrees researchers and clinicians to select the most appropriate tools for their specific applications, whether it's whole-genome sequencing, targeted sequencing, or transcriptome analysis. Additionally, a broad portfolio can include specialized offerings such as kits for cancer genomics, microbiome studies, and rare disease research, further appealing to a wide range of customers across academia, healthcare, and industry.
Opportunity
- Increasing Advancement in NGS Technology
Enhanced sequencing speed, accuracy, scalability, and cost-effectiveness, have significantly expanded the applications of NGS across various fields such as genomics, oncology, and infectious diseases. This expansion of applications has not only increased the demand for NGS technologies but has also opened up new markets. In addition, the decreasing cost of sequencing has made NGS more accessible to researchers, clinicians, and patients, further driving its adoption in clinical diagnostics and personalized medicine. Furthermore, ongoing technological innovations, such as the development of long-read sequencing technologies and portable sequencing devices, continue to recover the performance and usability of NGS platforms, enhancing their value proposition for customers.
Restraint/Challenge
- Complexity During Implementation of NGS in the Clinical Lab
The implementation of next generation sequencing (NGS) in clinical laboratories faces several restraints that can impede the growth of the NGS market. One major restraint is the complexity and variability of NGS data. The huge amount of genetic data generated requires sophisticated bioinformatics tools for analysis and interpretation. Clinical labs must invest in these resources and skilled personnel to ensure accurate and actionable results, which can be a barrier to adoption. Another restraint is the demand for advanced instrumentation and specialized equipment for NGS. These instruments can be expensive, and maintaining them requires a significant investment in infrastructure and technical expertise. Smaller clinical labs may struggle to justify the cost of these investments, limiting the widespread implementation of NGS.
Recent Developments
- In April 2024, Merck KGaA has introduced the industry's first all-in-one, validated genetic stability assay. The Aptegra CHO genetic stability assay uses whole genome sequencing and bioinformatics to speed up biosafety testing for clients, facilitating their transition to commercial production. This innovation will help Merck KGaA streamline biosafety testing for clients, enabling faster transitions to commercial production and enhancing their competitiveness in the market
- In January 2024, QIAGEN has upgraded its QIAGEN CLC Genomics Workbench Premium with LightSpeed technology to include support for next-generation sequencing (NGS) in somatic cancer secondary analysis. This software accelerator efficiently converts raw sequencing data from FASTQ files to interpretable lists of genetic variants in VCF files at a remarkably low cost and high speed. This upgrade strengthens QIAGEN's offering, providing customers with a faster, cost-effective solution for somatic cancer NGS analysis, enhancing their competitiveness
- In January 2024, Beckman Coulter, Inc. has partnered with Polycarbin, a trailblazer in sustainable laboratory solutions. Together, they aim to revolutionize lab sustainability for liquid handling automation plastics. This collaboration merges Beckman Coulter Life Sciences' expertise in automated liquid handling with Polycarbin's circular economy platform, focusing on sustainability in laboratory plastics
- In November 2023, QIAGEN and DNA Labs International have collaborated to solve two decades-old cold cases using QIAGEN's ForenSeq Kintelligence System for forensic genetic genealogy, in conjunction with the GEDmatch PRO database. This highlights the effectiveness and increasing adoption of this approach to human identification. This will result in effectiveness of QIAGEN's forensic genetic genealogy solutions, potentially boosting their adoption and sales in the forensic market
- In November 2023, Beckman Coulter, Inc. has entered into a collaboration agreement with Pillar Biosciences, a developer and distributor of IVD & RUO NGS testing solutions using their proprietary SLIMamp technology. As part of the agreement, Pillar Biosciences will create a series of applications for use on the Biomek NGeniuS Next Generation Library Preparation System. This collaboration will enhance Beckman Coulter's offerings by integrating Pillar Biosciences' advanced NGS testing solutions, benefiting cancer patients through improved precision therapy selection
- In November 2023, QIAGEN and Element Biosciences, Inc. have announced a strategic partnership to provide comprehensive next-generation sequencing (NGS) workflows for the Element AVITI System, an innovative sequencing platform. This partnership will expand QIAGEN's portfolio of NGS workflows and strengthen its position in the genomics market
- In October 2023, Beckman Coulter, Inc. and 10x Genomics have partnered to enhance automation solutions for single-cell assay workflows. Under this collaboration, 10x Genomics will develop Chromium Single Cell kits tailored for use with Beckman Coulter Life Sciences' Biomek i7 Automated Liquid Handler. This customized application aims to automate 10x Genomics' single-cell library preparation, ensuring high-quality, large-scale production of finished libraries ready for sequencing. This partnership will enable Beckman Coulter to offer enhanced automation solutions for single-cell assays, providing customers with streamlined workflows and improved efficiency
- In October 2023, Azenta US, Inc. announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will host GENEWIZ Week from November 6-10, 2023. The event will include virtual workshops, promotions, and a grant program for genomics research excellence. Hosting GENEWIZ Week enhanced Azenta's brand visibility, attract new customers, and foster collaborations in the genomics research community, ultimately driving growth and innovation
- In September 2023, Charles River Laboratories and PathoQuest SAS, a provider of next-generation sequencing (NGS) testing services for biopharmaceuticals, announced that they have jointly published groundbreaking research in Vaccine. This study highlighted the superior viral contaminant detection capabilities of PathoQuest's proprietary, good manufacturing practice (GMP) grade NGS-based assay compared to in vivo assays. This achievement will enhance the company's reputation and position it as a leader in biopharmaceutical testing, potentially attracting more clients seeking advanced and reliable testing solutions
- In May 2023, Charles River Laboratories has introduced Accugenix Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix NGS). This technology sequences millions of individual DNA fragments from a sample, offering pharmaceutical and personal care manufacturers crucial microbial control information. The new technology enhances the company's services, offering pharmaceutical and personal care manufacturers advanced microbial control solutions that improve product quality and regulatory compliance
Global Next Generation Sequencing (NGS) Market Scope
The global next generation sequencing (NGS) market is segmented into five notable segments based on product & service, technology, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product & Service
- Consumables
- Services
- Instruments
On the basis of product & service, the global next generation sequencing (NGS) market is segmented into consumables, services, and instruments.
Technology
- Sequencing by Synthesis (SBS)
- Sequencing by Ligation (SBL)
- Others
On the basis of technology, the global next generation sequencing (NGS) market is segmented into Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), and others.
Application
- Pharmaceuticals Microbiology
- Drug & Biomarker Discovery
- Diagnostics
- Precision Medicine
- Agricultural & Animal Research
- Food Pathogen Screening
- Others
On the basis of application, the global next generation sequencing (NGS) market is segmented into pharmaceuticals microbiology, drug & biomarker discovery, diagnostics, precision medicine, agricultural & animal research, food pathogen screening, and others.
End user
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospitals & Clinics
- Clinical Laboratories
- Contract Research Organizations (CROS)
- Others
On the basis of end user, the global next generation sequencing (NGS) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories, Contract Research Organizations (CROS), and others.
Distribution channel
- Direct tender
- Retail sales
- Others
On the basis of distribution channel, the global next generation sequencing (NGS) market is segmented into direct tender, retail sales, and others.
Global Next Generation Sequencing (NGS) Market Regional Analysis/Insights
The global next generation sequencing (NGS) market is analyzed, and market size insights and trends are provided by based on product & service, technology, application, end user, and distribution channel as referenced above.
The countries covered in this global next generation sequencing (NGS) market report are U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.
North America is expected to dominate the global next generation sequencing (NGS) market due to factors such as the presence of a huge number of key market players, high adoption of NGS technologies in research and clinical applications, and favorable government initiatives and funding supporting genomics research.
U.S. is expected to dominate in the North America next generation sequencing (NGS) market due to factors such as the presence of a large number of NGS technology providers, significant investments in genomic research, and a supportive regulatory environment promoting the adoption of NGS in clinical and research settings.
U.K. is expected to dominate in the Europe next generation sequencing (NGS) market due to its advanced healthcare infrastructure, strong government support for genomic research, and a well-established market for NGS technologies and services.
China is expected to dominate in the Asia-Pacific next generation sequencing (NGS) market due to its large population, increasing adoption of precision medicine, government initiatives to promote genomics research, and a growing number of NGS technology providers in the region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Next Generation Sequencing (NGS) Market Share Analysis
The global next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the global next generation sequencing (NGS) market.
Some of the major players operating in the global next generation sequencing (NGS) market are Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Merck KGaA, Charles River Laboratories, Revvity, Promega Corporation., Agilent Technologies, Inc., Takara Bio Inc., Eurofins Scientific, Hamilton Company, BGI, Azenta US, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., PacBio., Macrogen, Inc., Gilson Incorporated, New England Biolabs, Oxford Nanopore Technologies plc., LGC Biosearch Technologies, PCR Biosystems, ACT Genomics, Quantabio, DNASTAR, and NimaGen. among others.
SKU-